Form 8-K - Current report

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 14, 2024

EVOME MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)

British Columbia	333-255642	Not Applicable
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

49 Natcon Dr
Shirley, New York, United States 11967
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: [phone]

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Directors

On February 14, 2024, the Board appointed Wayne Anderson and Bill Garbarini to the Board of Directors of Evome Medical Technologies Inc. (the "Company"), to serve as directors on the Board until the Company's next annual meeting of shareholders and until their respective successors are duly elected and qualified.

Mr. Anderson was the President and CEO of Ferring Pharmaceuticals USA from 1997 to 2010.‎  Mr. Garbarini has been Chief Executive Officer of Conceivable Life Sciences, a venture backed in-vitro fertilization company since January 2023, and was a Ferring Pharmaceuticals USA executive from 2001 to 2015.  Mr. Anderson  and Mr. Garbarini will serve on the Audit Committee of the Board, along with Ken Kashkin.  With the appointment of the new directors, the total number of directors on the Board will be five.

There are no understandings or arrangements between Mr. Anderson, Mr. Garbarini or any other person and the Company or any of its subsidiaries pursuant to which either Mr. Anderson or Mr. Garbarini was selected to serve as a director of the Company. There are also no transactions involving either Mr. Anderson or Mr. Garbarini that would warrant disclosure pursuant to Item 404 of Regulation S-K.

Item 7.01. Regulation FD Disclosure.

On February 15, 2024, the Company issued a press release announcing, among other things, the appointment of Mr. Anderson and Mr. Garbarini to the Board of Directors. A copy of such press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.  This information is furnished pursuant to Item 7.01 "Regulation FD Disclosure," and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01.    Financial Statements and Exhibits.

(d)    Exhibits.

Exhibit No.	Description
99.1	Press Release of Evome Medical Technologies Inc. dated February 15, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

	EVOME MEDICAL TECHNOLOGIES INC.
Date:  February 15, 2024	By:	/s/ Michael Seckler
	Name: Michael Seckler
	Title: Chief Executive Officer

---

---

EXHIBIT 99.1  

Evome Medical Technologies Bolsters Board of Directors with Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman

New York, New York, February 15, 2024 - Evome Medical Technologies Inc. (the "Company" or "Evome") announces the appointment of two senior healthcare executives to its Board of Directors.‎

Mr. Wayne Anderson, former President and CEO of Ferring Pharmaceuticals USA, has joined as a non-executive ‎member of the Board of Directors.‎

Mr. Bill Garbarini, a former Ferring Pharmaceuticals USA executive and current COO of Conceivable Life Sciences, a venture backed in-vitro fertilization company, will also join as a non-executive member of the Board of Directors.

In addition, Kenneth Kashkin, MD, has been appointed Chairman of the Board of Directors. Dr. Kashkin is Board Certified in Internal Medicine, Neurology & Psychiatry with training at, and serving on, the faculties of the University of California, Los Angeles (UCLA) and Yale University Schools of Medicine. He has led development at divisions of Bayer, Abbott, Knoll/BASF Pharma and Baxter.

‎"Now that we have successfully executed on our turnaround plan, I am pleased to have Wayne and Bill join the ‎Board," said Mike Seckler, CEO of Evome. "I worked with both of these talented and successful healthcare executives for many years while at Ferring and I am eager to benefit from their valuable guidance and expertise, ‎particularly in the realms of product launch and commercialization.  Dr. Kashkin's contributions will play a crucial role in advancing our innovation and development strategies, aligning with our vision to democratize our ‎Biodex Brands. I can now say we have completed all of the necessary steps to transform our company. We ‎have driven revenue growth, developed new products, cut costs and restructured our debt. The final step was ‎to add some seasoned talent to our Board to assist us in driving shareholder value."‎

For more information please contact:‎

‎ ‎

Mike Seckler

Chief Executive Officer

Tel: [phone]‎

Email: [e-mail]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the ‎policies of ‎‎the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this ‎release.‎

---

Document and Entity Information Document	Feb. 14, 2024
Document Information [Line Items]
Document Type	8-K
Document Creation Date	Feb. 14, 2024
Document Period End Date	Feb. 14, 2024
Amendment Flag	false
Entity Registrant Name	Evome Medical Technologies Inc.
Entity Address, Address Line One	49 Natcon Dr
Entity Address, City or Town	Shirley
Entity Address, State or Province	NY
Entity Address, Country	US
Entity Address, Postal Zip Code	11967
Entity Incorporation, State Country Name	A1
City Area Code	800
Local Phone Number	760-6826
Entity File Number	333-255642
Entity Central Index Key	0001617765
Entity Emerging Growth Company	true
Entity Tax Identification Number	00-0000000
Entity Ex Transition Period	false
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false

---